JP2006506368A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506368A5
JP2006506368A5 JP2004544849A JP2004544849A JP2006506368A5 JP 2006506368 A5 JP2006506368 A5 JP 2006506368A5 JP 2004544849 A JP2004544849 A JP 2004544849A JP 2004544849 A JP2004544849 A JP 2004544849A JP 2006506368 A5 JP2006506368 A5 JP 2006506368A5
Authority
JP
Japan
Prior art keywords
acid
salt
isomer
benzhydryl
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004544849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/032275 external-priority patent/WO2004035575A1/en
Publication of JP2006506368A publication Critical patent/JP2006506368A/ja
Publication of JP2006506368A5 publication Critical patent/JP2006506368A5/ja
Pending legal-status Critical Current

Links

JP2004544849A 2002-10-16 2003-10-10 (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法 Pending JP2006506368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16
PCT/US2003/032275 WO2004035575A1 (en) 2002-10-16 2003-10-10 Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine

Publications (2)

Publication Number Publication Date
JP2006506368A JP2006506368A (ja) 2006-02-23
JP2006506368A5 true JP2006506368A5 (enExample) 2006-11-30

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544849A Pending JP2006506368A (ja) 2002-10-16 2003-10-10 (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法

Country Status (21)

Country Link
US (2) US6861526B2 (enExample)
EP (1) EP1551833A4 (enExample)
JP (1) JP2006506368A (enExample)
KR (1) KR100739901B1 (enExample)
CN (1) CN100418964C (enExample)
AP (1) AP2005003288A0 (enExample)
AR (1) AR041587A1 (enExample)
AU (1) AU2003277353B2 (enExample)
BR (1) BR0315335A (enExample)
CA (1) CA2500635A1 (enExample)
EA (1) EA008192B1 (enExample)
HR (1) HRP20050328A2 (enExample)
IS (1) IS7755A (enExample)
MX (1) MXPA05004058A (enExample)
PA (1) PA8586601A1 (enExample)
PE (1) PE20040777A1 (enExample)
PL (1) PL376218A1 (enExample)
TN (1) TNSN05111A1 (enExample)
UY (1) UY28024A1 (enExample)
WO (1) WO2004035575A1 (enExample)
ZA (1) ZA200502411B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
HUE034099T2 (en) * 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
DK1713801T3 (da) * 2004-02-02 2008-03-17 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
WO2025172911A1 (en) * 2024-02-16 2025-08-21 Teadus Pharmaceuticals Pvt. Ltd A process for the preparation of (2s,3s)-2-benzhydryl- n-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine and pharmaceutically acceptable salts thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
RU2092486C1 (ru) * 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
BR9206073A (pt) 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
JP2909214B2 (ja) 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
NZ254604A (en) 1992-11-12 1997-06-24 Pfizer Quinuclidine derivative and pharmaceutical compositions thereof
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Similar Documents

Publication Publication Date Title
KR100739901B1 (ko) (s,s)-시스-2-벤즈하이드릴-3-벤질아미노퀴누클리딘의제조 방법
JP4921646B2 (ja) 1−(3−ベンジルオキシプロピル)−5−(2−置換プロピル)インドリン誘導体およびその使用方法
JP2009527517A5 (enExample)
CN103664677A (zh) 一种(r,r)-福莫特罗酒石酸盐的不对称合成方法
TW200900376A (en) Method for producing 4-aminomethylbenzoic acid
CN101585798A (zh) 光学活性化合物1-(3-苯甲酰氧基丙基)-5-(2-(1-苯基乙基胺)丙基)-7-氰基吲哚啉及其制备方法和用途
JP2013512276A5 (enExample)
JP4079727B2 (ja) 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法
EP1224161B1 (en) Nitroxy derivatives of (r) and (s)-carnitine
CN100422138C (zh) 生产旋光活性1-烷基-取代的2,2,2-三氟乙基胺的方法
JP2002544252A5 (enExample)
JP3982993B2 (ja) 光学活性1−(トリフルオロメチルモノ置換フェニル)エチルアミンの精製方法
JP2005298334A (ja) 新規な中間体化合物およびそれを用いる化合物の製造方法
JP4806763B2 (ja) 光学活性l−エリトロ−2−アミノ−1−フェニル−1−プロパノールの製造方法
JP4320870B2 (ja) (+)−トランス第一菊酸の製造方法
WO2013058241A1 (ja) (r)-2-アミノ-2-エチルヘキサノールの製造法
WO2008001719A1 (en) Method for producing optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl)alkylamine n-monoalkyl derivative
CN1058488C (zh) 1,3,6-三烷基六氢-1,3,6-三氮杂辛因-2-酮及其制备方法
CN113264839B (zh) 一种使用手性辅基制备左旋特布他林的方法
JP7601462B2 (ja) 不斉補助剤を使用してレボテルブタリンを調製する方法
JP2015166383A (ja) ネラメキサン又はその塩を調製する方法
CN116693409A (zh) 一种(2s)-[4-(3-氟苄氧基)苄胺基]丙酸甲酯的制备方法
JP2003252837A (ja) 光学活性エリスロ型アミノアルコールの製造方法
JP5749261B2 (ja) 3,3,5,5−テトラメチルシクロヘキサノンを調製する方法
JP4314602B2 (ja) 光学活性3−ヒドロキシピロリジン誘導体の製造方法